Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

Author(s): Bowtell, DD; Bohm, S; Ahmed, AA; Aspuria, PJ; Bast, RC, Jr; Beral, V; Berek, JS; Birrer, MJ; Blagden, S; Bookman, MA; Brenton, JD; Chiappinelli, KB; Martins, FC; Coukos, G; Drapkin, R; Edmondson, R; Fotopoulou, C; Gabra, H; Galon, J; Gourley, C; Heong, V; Huntsman, DG; Iwanicki, M; Karlan, BY; Kaye, A; Lengyel, E; Levine, DA; Lu, KH; McNeish, IA; Menon, U; Narod, SA; Nelson, BH; Nephew, KP; Pharoah, P; Powell, DJ, Jr; Ramos, P; Romero, IL; Scott, CL; Sood, AK; Stronach, EA; Balkwill, FR;
Details: Publication Year 2015-10-23,Volume 15,Issue #11,Page 668-79
Journal Title: Nat Rev Cancer
Publication Type: Journal Article
Abstract: High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.
Publisher: NPG
Research Division(s): Stem Cells And Cancer
PubMed ID: 26493647
Publisher's Version: https://doi.org/10.1038/nrc4019
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2015-10-28 01:52:44

Last Modified: 2015-10-28 01:56:41